Natural product-derived therapy for attenuating pathogenesis-associated with Myocardial infarction: A pharmaceutical mixture encompassing Sulforaphane, Myricitrin, and Aspalathin (SMA) decreases IRF3, GM-CSF (Granulocyte-macrophage colony-stimulating factor) and GRK2(G protein-coupled receptor kinase) expression, inhibits undue leucocyte activation and invasion, suppresses recruitment of inflmmatory cells, inhibits ventricular dilation, and promotes heart repair and survival via up regulation of its target gene, 11/January/2017, 11.48 pm

Introduction: What they say: A recent study from Department of Systems Biology, Harvard Medical School, Boston, Massachusetts, USA; and Cardiovascular Research Center, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA shows that “IRF3 and type I interferons fuel a fatal response to myocardial infarction.” This study was published, in the 6 November 2017 […]

Vitamin-based therapy for improving cardiac contractility and attenuating pathogenesis-associated with Myocardial infarction:   Phytonadione/Mephyton/VitaminK1  decreases GRK2 (G Protein-Coupled Receptor Kinase 2) and GM-CSF (Granulocyte-macrophage colony-stimulating factor) expression, increases cardiac contractility, inhibits undue leucocyte activation and invasion, suppresses recruitment of inflammatory cells, inhibits left ventricular rupture, promotes heart healing and inhibits glucose intolerance, via up regulation of its target gene, 4/January/2017, 6.17 am

Introduction: What they say: A recent study, from Department of Medicine, Division of Cardiology, Dept of Cell Biology, and Department of Molecular Genetics, Duke University Medical Center, Durham, North Carolina, USA, shows that “Mdm2 regulates cardiac contractility by inhibiting GRK2-mediated desensitization of ß-adrenergic receptor signaling.” This study was published, in the 7 September 2017 issue […]

Molecular therapy for Cardiomyopathy: A pharmacological mixture encompassing VitaminK1 (Phytonadione/Mephyton) and Asprin (VKASP) decreases the expression of Sox6, restores the balance between slow- and fast-twitch myofiber proteins and alleviates Cardiomyopathy via up regulation of its target gene, 4/January/2018,  5.48 am

Introduction: What they say   A study from the Department of Cardiology, Boston Children’s Hospital, Harvard Medical School, Boston, Massachusetts, USA; and Harvard Stem Cell Institute, Harvard University, Cambridge, Massachusetts, USA shows that “Trbp regulates heart function through microRNA-mediated Sox6 repression.” This study was published, in the 2 June  2015 issue of the journal “Nature Genetics” (the number 1 research journal in Genetics with an impact factor of 29.648), by Prof. Da-Zhi Wang & Jian Ding, and […]

Regenerative therapy for regaining the lost cardiomyocytes in Myocardial patients:  A pharmaceutical mixture [PMEET] encompassing Pyridoxamine (PM-a form of Vitamin-B (6)) and 14, 15 Epoxyeicosatrienoic acid (14, 15-EET)  increases the expression of ERBB2/Her2 and promotes dedifferentiation  of cardiomyocytes via down regulation of its target gene, 26/December/2017, 11.49 pm

Introduction: What they say A recent study from the Department of Biological Regulation, Weizmann Institute of Science, Rehovot 76100, Israel shows that “ERBB2 triggers mammalian heart regeneration by promoting cardiomyocyte dedifferentiation and proliferation.” This study was published, in the 6 April  2015 issue of the journal “Nature cell biology” (the number 1 journal in “Cell biology” research with an impact factor of 20.761), by Prof Tzahor E, D’Uva E, and others. What […]

Combinatorial therapy for improving cardiac contractility and attenuating pathogenesis associated with Myocardial infarction: A pharmaceutical mixture encompassing Matrine, Epicatechin, 14, 15, Epoxyeicosatrienoicacids (14, 15 EETs) (MEEET)  decreases GRK2 (G Protein-Coupled Receptor Kinase 2) and GM-CSF (Granulocyte-macrophage colony-stimulating factor) expression, increases cardiac contractility, inhibits undue leucocyte activation and invasion, suppresses recruitment of inflammatory cells, inhibits left ventricular rupture, promotes heart healing and inhibits glucose intolerance, via up regulation of its target gene, 25/December/2017, 1.37 am

Introduction: What they say: A recent study, from Department of Medicine, Division of Cardiology, Dept of Cell Biology, and Department of Molecular Genetics, Duke University Medical Center, Durham, North Carolina, USA, shows that “Mdm2 regulates cardiac contractility by inhibiting GRK2-mediated desensitization of ß-adrenergic receptor signaling.” This study was published, in the 7 September 2017 issue […]

Molecular therapy for Cardiomyopathy: Lycopene (LYC), isolated from Gac, Guava, and Tomatoes, among others, decreases the expression of Sox6, restores the balance between slow- and fast-twitch myofiber proteins and alleviates Cardiomyopathy via up regulation of its target gene, 24/December/2017,  12.51 am

Introduction: What they say   A study from the Department of Cardiology, Boston Children’s Hospital, Harvard Medical School, Boston, Massachusetts, USA; and Harvard Stem Cell Institute, Harvard University, Cambridge, Massachusetts, USA shows that “Trbp regulates heart function through microRNA-mediated Sox6 repression.” This study was published, in the 2 June  2015 issue of the journal “Nature Genetics” (the number 1 research journal in Genetics with an impact factor of 29.648), by Prof. Da-Zhi Wang & Jian Ding, and […]